NO944340D0 - Melatoninderivater for anvendelse ved behandling av desynkroniseringstilstander - Google Patents

Melatoninderivater for anvendelse ved behandling av desynkroniseringstilstander

Info

Publication number
NO944340D0
NO944340D0 NO944340A NO944340A NO944340D0 NO 944340 D0 NO944340 D0 NO 944340D0 NO 944340 A NO944340 A NO 944340A NO 944340 A NO944340 A NO 944340A NO 944340 D0 NO944340 D0 NO 944340D0
Authority
NO
Norway
Prior art keywords
desynchronization
states
treatment
melatonin derivatives
melatonin
Prior art date
Application number
NO944340A
Other languages
English (en)
Other versions
NO307364B1 (no
NO944340L (no
Inventor
Michael Edward Flaugh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944340D0 publication Critical patent/NO944340D0/no
Publication of NO944340L publication Critical patent/NO944340L/no
Publication of NO307364B1 publication Critical patent/NO307364B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO944340A 1993-11-18 1994-11-14 Anvendelse av melatoninderivater NO307364B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/154,903 US6180657B1 (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating desynchronization disorders

Publications (3)

Publication Number Publication Date
NO944340D0 true NO944340D0 (no) 1994-11-14
NO944340L NO944340L (no) 1995-05-19
NO307364B1 NO307364B1 (no) 2000-03-27

Family

ID=22553300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944340A NO307364B1 (no) 1993-11-18 1994-11-14 Anvendelse av melatoninderivater

Country Status (21)

Country Link
US (1) US6180657B1 (no)
EP (1) EP0656209B1 (no)
JP (1) JPH07196504A (no)
KR (1) KR950013509A (no)
CN (1) CN1100533C (no)
AT (1) ATE239470T1 (no)
AU (1) AU7777694A (no)
CA (1) CA2135710C (no)
CZ (1) CZ288834B6 (no)
DE (1) DE69432626T2 (no)
DK (1) DK0656209T3 (no)
ES (1) ES2197904T3 (no)
HU (1) HUT72070A (no)
IL (1) IL111579A (no)
NO (1) NO307364B1 (no)
NZ (1) NZ264893A (no)
PT (1) PT656209E (no)
RU (1) RU2160101C2 (no)
SG (1) SG77569A1 (no)
UA (1) UA35588C2 (no)
ZA (1) ZA948928B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (en) * 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
CA2551117A1 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc. Substituted melatonin derivatives, process for their preparation, and methods of use
TWI402261B (zh) 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
JP2011520923A (ja) * 2008-05-19 2011-07-21 武田薬品工業株式会社 細胞傷害性抗癌モノクローナル抗体
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3085116C (en) 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN110200958A (zh) 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
RU2533965C1 (ru) * 2013-07-04 2014-11-27 Государственное бюджетное учреждение здравоохранения "Самарский областной гериатрический центр" Способ нормализации циркадианных ритмов человека
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
RU2655813C1 (ru) * 2017-06-09 2018-05-29 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4614807A (en) 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
WO1989001472A1 (en) 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
AU660336B2 (en) * 1991-10-18 1995-06-22 Alza Corporation Device for the transdermal administration of melatonin
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
DE69432626T2 (de) 2004-04-08
ZA948928B (en) 1996-05-10
JPH07196504A (ja) 1995-08-01
RU94041028A (ru) 1996-09-20
AU7777694A (en) 1995-05-25
UA35588C2 (uk) 2001-04-16
ES2197904T3 (es) 2004-01-16
CA2135710C (en) 2007-07-10
IL111579A (en) 1999-10-28
CN1107700A (zh) 1995-09-06
NZ264893A (en) 1997-06-24
EP0656209B1 (en) 2003-05-07
HUT72070A (en) 1996-03-28
NO307364B1 (no) 2000-03-27
DK0656209T3 (da) 2003-09-01
CZ288834B6 (cs) 2001-09-12
SG77569A1 (en) 2001-01-16
CZ276494A3 (en) 1995-07-12
CA2135710A1 (en) 1995-05-19
EP0656209A3 (en) 1995-10-11
DE69432626D1 (de) 2003-06-12
KR950013509A (ko) 1995-06-15
NO944340L (no) 1995-05-19
EP0656209A2 (en) 1995-06-07
CN1100533C (zh) 2003-02-05
IL111579A0 (en) 1995-01-24
ATE239470T1 (de) 2003-05-15
HU9403299D0 (en) 1995-01-30
PT656209E (pt) 2003-09-30
US6180657B1 (en) 2001-01-30
RU2160101C2 (ru) 2000-12-10

Similar Documents

Publication Publication Date Title
EP0751709A4 (en) METHODS FOR USE OF BCL-2 IN THERAPEUTIC TREATMENT AND PREVENTION OF DISEASES
DK0651754T3 (da) K-252a-derivater
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
EP0651650A4 (en) METHOD FOR TREATING EYE DISEASES BY MEANS OF TGF - g (b).
NO944340D0 (no) Melatoninderivater for anvendelse ved behandling av desynkroniseringstilstander
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
DK0693912T3 (da) Apparat til medicinsk behandling
EA199900862A1 (ru) Способ лечения сосудистых нарушений
SI1304107T1 (en) Use of oxazolidinines derivatives for treating psoriasis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees